Telehealth companies are moving GLP-1 drugs into addiction care before regulators weigh in
GLP-1 medications have already reshaped obesity care and diabetes treatment. Now they are being marketed for a different target: addiction, with alcohol use disorder emerging as the leading example in telehealth advertising and prescribing.
Several startups, including Quel, Livelyhood, and Choose Your Horizon, are already offering off-label prescriptions of popular obesity drugs to people struggling with substance use. Some are also promoting compounded versions that have not been approved by regulators. The clinical question is no longer whether these drugs might influence addictive behavior in some patients. The more immediate issue is how quickly commercial care models are racing ahead of formal review, dosing standards, and long-term safety data.
Off-label prescribing is moving faster than the evidence base
The appeal is understandable. GLP-1 agents act on pathways involved in appetite, reward, and satiety, and that biology has encouraged interest far beyond weight loss. In addiction medicine, reward circuitry is central to compulsive use, craving, and relapse. A drug class already familiar to patients and clinicians may seem like a plausible shortcut toward reducing alcohol intake or dampening other substance-related behaviors.
Still, plausibility is not the same as regulatory authorization. These products are being prescribed for addiction before the FDA has weighed in on that specific use. In practice, that places telehealth companies in a gray zone where clinical enthusiasm, consumer demand, and commercial incentive intersect. Prescribers can legally use approved drugs off-label, but the speed and scale of online promotion raise a different concern: whether patients are being offered treatments before the field has settled on who should receive them, at what dose, and with what monitoring.
The compounding issue complicates matters further. Compounded versions are not approved by regulators, which means the quality, consistency, and equivalence of those products may vary. For patients seeking help with substance use, a therapy marketed as accessible and modern can still carry unresolved questions about formulation integrity and real-world safety oversight.
Alcohol use disorder is becoming the first commercial test case
Alcohol use disorder appears to be the condition attracting the most immediate attention. That makes clinical sense, because it is common, chronic, and often undertreated. It also creates an opening for companies eager to position GLP-1s as a broad behavioral treatment rather than a narrow metabolic one.
The logic rests on more than marketing language. If a medication can alter reward salience, reduce craving, or blunt the reinforcement associated with drinking, then alcohol consumption may fall as a downstream effect. Yet the pathway from mechanistic theory to durable benefit is not automatic. Addiction treatment depends on sustained engagement, psychosocial support, relapse prevention, and careful follow-up. A prescription issued through a telehealth checkout flow cannot substitute for those elements, even when the drug itself is biologically interesting.
One sentence captures the tension: commercial access is outpacing clinical certainty.
Safety, oversight, and the limits of rapid expansion
The move into addiction treatment also raises practical safety questions. Patients with substance use disorders often have complex medical and psychiatric comorbidity, fluctuating follow-up, and concurrent medications. Those realities make prescribing more than a transaction. They demand assessment of contraindications, side effects, adherence, and whether the patient has enough support to stay on treatment if nausea, appetite suppression, or other tolerability issues become barriers.
Compounded formulations intensify those concerns. When a product has not been approved by regulators, clinicians cannot rely on the same evidence base that supports branded medications in their approved indications. The situation is especially sensitive when companies market directly to consumers who may be desperate for help and may assume that a familiar obesity drug carries the same evidentiary weight in addiction care as it does in metabolic disease.
A second sentence stands on its own: no FDA approval exists for GLP-1 use in addiction treatment.
That absence does not prohibit research or off-label prescribing, but it does shape the standard of caution. In addiction medicine, where patients are vulnerable to disappointment, relapse, and harmful substitution of one unproven strategy for another, credibility depends on transparent boundaries between hypothesis and established practice. A telehealth model built around rapid access can be useful when it lowers barriers to evidence-based care. It becomes more problematic when the speed of distribution substitutes for proof.
Commercial telehealth is testing the boundaries of evidence-based care
The current moment reflects a broader pattern in digital health: companies often identify a promising mechanism, package it for consumer access, and let demand set the pace. GLP-1s are especially attractive in that environment because the drugs already have name recognition and a strong public reputation tied to weight loss. Extending them into addiction treatment gives startups a ready-made narrative of innovation.
But addiction medicine has learned repeatedly that attractive mechanisms do not always translate into real-world benefit. Any medication used in this setting must be judged not only by biological plausibility but by whether it meaningfully reduces harmful use, improves retention in treatment, and does so safely across diverse patient groups. Those endpoints matter because patients with alcohol use disorder do not need another wellness experiment. They need therapies with clear evidence, durable follow-up, and honest communication about uncertainty.
For now, the most defensible reading of this trend is that telehealth companies are moving ahead of the formal regulatory process, betting that early consumer interest will outrun the lag between clinical hypothesis and official guidance. The absence of FDA review leaves clinicians to weigh off-label use against incomplete evidence, while compounded products add another layer of uncertainty. Until controlled data and regulatory decisions catch up, the field will remain split between pharmacologic promise and premature commercialization.